PreserFlo MicroShunt versus trabeculectomy: an updated meta-analysis and systematic review.
Glaucoma
Intraocular pressure
PreserFlo
Trabeculectomy
Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248
Informations de publication
Date de publication:
12 Oct 2024
12 Oct 2024
Historique:
received:
27
05
2024
accepted:
24
09
2024
revised:
13
09
2024
medline:
12
10
2024
pubmed:
12
10
2024
entrez:
11
10
2024
Statut:
aheadofprint
Résumé
This meta-analysis compares PreserFlo (PF) and trabeculectomy (TB) in moderate-to-advanced glaucoma (defined by visual fields with a mean deviation (MD) worse than -6 dB). Key outcomes include success rates (qualified success is defined as a target IOP of less than 21 mm Hg or a 20% reduction from baseline at the endpoint, with or without medications. Complete success is achieving these targets without any medications), intraocular pressure (IOP), complications, reinterventions, needling, glaucoma medication reduction, retinal nerve fibre layer (RNFL), and visual field progression. We searched PubMed, Scopus, and Cochrane Central up to 13/01/24, including randomized and non-randomized studies with at least 2 months follow-up. Bias risk was assessed using ROB-2 for RCTs and ROBIN-I for non-RCTs. Publication bias was evaluated via funnel plots and Egger's regression. Ten studies (n = 1833 eyes; 57.4% PF) were analyzed. Preoperative IOP was 22.1 mmHg; 56.1% had moderate-to-severe glaucoma. No significant differences were found in qualified (QSR) and complete success rates (CSR) between PF and TB. Trabeculectomy achieved better IOP outcomes (mean difference, MD 1.59 mmHg; p = 0.0004) and greater IOP reduction (MD -2.52 mmHg; p = 0.0003), but PF showed less visual field progression (MD -1.21; p = 0.03) and lower hypotony maculopathy risk (OR 0.30; p = 0.03). PF had a higher reintervention rate, particularly in patients without prior glaucoma surgery (OR 1.74; p = 0.02) or with primary open-angle glaucoma (OR 1.84; p = 0.04). Trabeculectomy is more effective for uncontrolled glaucoma up to 2 years, while PF presents a lower risk of hypotony-related events and may benefit patients sensitive to visual field progression. Study strengths include detailed subgroup analyses and mid-term follow-up, with limitations noted in the number of RCTs. What is known PreserFlo MicroShunt has been shown to provide an efficient surgical solution for intraocular pressure (IOP) control with a favourable safety profile. Compared to trabeculectomy thereis still contentious regarding the best surgical approach. What is new Trabeculectomy is more effective in uncontrolled glaucoma patients up to 2 years, particularly if lower target IOPs are considered. PreserFlo had lower hypotony-related events risk and may be preferred for patients sensitive to visual field loss. PreserFlo showed a higher risk of reintervention, especially without prior glaucoma surgery or primary open-angle glaucoma diagnosis.
Identifiants
pubmed: 39394492
doi: 10.1007/s00417-024-06649-w
pii: 10.1007/s00417-024-06649-w
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Anon (2021) European glaucoma society terminology and guidelines for glaucoma, 5th Edition. Br J Ophthalmol 105:1–169
Cairns JE (1968) Trabeculectomy. Am J Ophthalmol 66:673–679
doi: 10.1016/0002-9394(68)91288-9
pubmed: 4891876
Gedde SJ, Herndon LW, Brandt JD et al (2012) Postoperative complications in the tube versus trabeculectomy (TVT) study during five years of follow-up. Am J Ophthalmol 153:804-814.e1
doi: 10.1016/j.ajo.2011.10.024
pubmed: 22244522
pmcid: 3653167
Gedde SJ, Feuer WJ, Lim KS et al (2020) Treatment outcomes in the primary tube versus trabeculectomy study after 3 years of follow-up. Ophthalmology 127:333–345
doi: 10.1016/j.ophtha.2019.10.002
pubmed: 31727428
Cheema AA, Cheema HR (2024) The evolution and current landscape of minimally invasive glaucoma surgeries: a review. Cureus 16:e52183
pubmed: 38264176
pmcid: 10804217
Health O (2024) Minimally invasive bleb surgery for glaucoma: a health technology assessment. Ont Health Technol Assess Ser 24:1–151
Pinchuk L, Wilson GJ, Barry JJ et al (2008) Medical applications of poly(styrene-block-isobutylene-block-styrene) (“SIBS”). Biomaterials 29:448–460
doi: 10.1016/j.biomaterials.2007.09.041
pubmed: 17980425
Acosta AC (2006) A newly designed glaucoma drainage implant made of poly(styrene-b-isobutylene-b-styrene): biocompatibility and function in normal rabbit eyes. Arch Ophthalmol 124:1742
doi: 10.1001/archopht.124.12.1742
pubmed: 17159034
Pinchuk L, Riss I, Batlle JF et al (2016) The use of poly(styrene- block -isobutylene- block -styrene) as a microshunt to treat glaucoma. Regen Biomater 3:137–142
doi: 10.1093/rb/rbw005
pubmed: 27047682
pmcid: 4817329
Luo N, Liu M, Hao M et al (2023) Comparison of tube shunt implantation and trabeculectomy for glaucoma: a systematic review and meta-analysis. BMJ Open 13:e065921
doi: 10.1136/bmjopen-2022-065921
pubmed: 37080625
pmcid: 10273552
Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13
doi: 10.1186/1471-2288-5-13
pubmed: 15840177
pmcid: 1097734
Heuer DK, Barton K, Grehn F, Shaarawy T, Sherwood M (2008) Consensus of definitions of success. In Shaarawy T, Grehn F & Sherwood M (eds). Guidelines on design and reporting of glaucoma surgical trials. World Glaucoma Association: Kugler Publications, The Hague, Amsterdam, The Netherlands, pp 15-2
Gedde SJ, Chen PP, Heuer DK et al (2018) The primary tube versus trabeculectomy study. Ophthalmology 125:774–781
doi: 10.1016/j.ophtha.2017.10.037
pubmed: 29248173
Higgins JPT, Altman DG, Gøtzsche PC et al (2011) The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928
doi: 10.1136/bmj.d5928
pubmed: 22008217
pmcid: 3196245
Sterne JA, Hernán MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919
doi: 10.1136/bmj.i4919
pubmed: 27733354
pmcid: 5062054
Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700
doi: 10.1136/bmj.b2700
pubmed: 19622552
pmcid: 2714672
Fili S, Kontopoulou K, Vastardis I et al (2022) PreserFlo™ microshunt versus trabeculectomy in patients with moderate to advanced open-angle glaucoma: 12-month follow-up of a single-center prospective study. Cureus 14:e28288
pubmed: 36158358
pmcid: 9494189
Hasan SM, Theilig T, Meller D (2023) Comparison of bleb morphology following PRESERFLO(®) microshunt and trabeculectomy using anterior segment OCT. Diagnostics (Basel) 13(21):3373
doi: 10.3390/diagnostics13213373
pubmed: 37958269
Wagner FM, Schuster AK, Munder A et al (2022) Comparison of subconjunctival microinvasive glaucoma surgery and trabeculectomy. Acta Ophthalmol 100:e1120–e1126
doi: 10.1111/aos.15042
pubmed: 34626093
Bøhler AD, Traustadóttir VD, Hagem AM et al (2023) Hypotony in the early postoperative period after MicroShunt implantation versus trabeculectomy: a registry study. Acta Ophthalmol 102(2):186–191
doi: 10.1111/aos.15727
pubmed: 37340695
Fu MX, Normando EM, Luk SMH et al (2022) MicroShunt versus trabeculectomy for surgical management of glaucoma: a retrospective analysis. J Clin Med 11(18):5481
doi: 10.3390/jcm11185481
pubmed: 36143128
pmcid: 9505905
Nobl M, Grün C, Kassumeh S et al (2023) One-year outcomes of Preserflo(TM) MicroShunt implantation versus trabeculectomy for pseudoexfoliation glaucoma. J Clin Med 12(8):3000
doi: 10.3390/jcm12083000
pubmed: 37109334
pmcid: 10141576
Gubser PA, Pfeiffer V, Hug S et al (2023) PRESERFLO MicroShunt implantation versus trabeculectomy for primary open-angle glaucoma: a two-year follow-up study. Eye Vis (Lond) 10:50
doi: 10.1186/s40662-023-00369-8
pubmed: 38124210
Jamke M, Herber R, Haase MA et al (2023) PRESERFLO ™ MicroShunt versus trabeculectomy: 1-year results on efficacy and safety. Graefes Arch Clin Exp Ophthalmol 261:2901–2915
doi: 10.1007/s00417-023-06075-4
pubmed: 37133501
pmcid: 10155172
Saeed E, Gołaszewska K, Dmuchowska DA et al (2023) The PreserFlo MicroShunt in the context of minimally invasive glaucoma surgery: a narrative review. Int J Environ Res Public Health 20:2904
doi: 10.3390/ijerph20042904
pubmed: 36833599
pmcid: 9957246
Pawiroredjo SSM, Bramer WM, Pawiroredjo ND et al (2022) Efficacy of the PRESERFLO MicroShunt and a meta-analysis of the literature. J Clin Med 11:7149
doi: 10.3390/jcm11237149
pubmed: 36498729
pmcid: 9738249
Batlle JF, Corona A, Albuquerque R (2021) Long-term results of the PRESERFLO MicroShunt in patients with primary open-angle glaucoma from a single-center nonrandomized study. J Glaucoma 30:281–286
doi: 10.1097/IJG.0000000000001734
pubmed: 33137019
Fea AM, Laffi GL, Martini E et al (2022) Effectiveness of MicroShunt in patients with primary open-angle and pseudoexfoliative glaucoma. Ophthalmol Glaucoma 5:210–218
doi: 10.1016/j.ogla.2021.08.005
pubmed: 34478904
Beckers HJM, Aptel F, Webers CAB et al (2022) Safety and effectiveness of the PRESERFLO® MicroShunt in primary open-angle glaucoma. Ophthalmol Glaucoma 5:195–209
doi: 10.1016/j.ogla.2021.07.008
pubmed: 34329772
Khan A, Khan AU (2024) Comparing the safety and efficacy of Preserflo Microshunt implantation and trabeculectomy for glaucoma: a systematic review and meta-analysis. Acta Ophthalmol 102(4):e443–e451
doi: 10.1111/aos.16658
pubmed: 38376121
Panarelli JF, Moster MR, Garcia-Feijoo J et al (2023) Ab-externo MicroShunt versus trabeculectomy in primary open-angle glaucoma: two-year results from a randomized multicenter study. Ophthalmology S0161–6420(23):00701–00707
Burgos-Blasco B, García-Feijóo J, Perucho-Gonzalez L et al (2022) Evaluation of a novel Αb externo MicroShunt for the treatment of glaucoma. Adv Ther 39:3916–3932
doi: 10.1007/s12325-022-02230-1
pubmed: 35797002
pmcid: 9402735
Pinchuk L, Riss I, Batlle JF et al (2017) The development of a micro-shunt made from poly(styrene- block -isobutylene- block -styrene) to treat glaucoma. J Biomed Mater Res 105:211–221
doi: 10.1002/jbm.b.33525
Ernest PJ, Schouten JS, Beckers HJ et al (2013) An evidence-based review of prognostic factors for glaucomatous visual field progression. Ophthalmology 120:512–519
doi: 10.1016/j.ophtha.2012.09.005
pubmed: 23211636
Anon (2016) Anesthetıc management in glaucoma surgery. ARC J Anesthesiol 1. Available at: https://www.arcjournals.org/pdfs/aja/v1-i3/2.pdf Accessed July 21, 2024
Law SK (2007) Severe loss of central vision in patients with advanced glaucoma undergoing trabeculectomy. Arch Ophthalmol 125:1044
doi: 10.1001/archopht.125.8.1044
pubmed: 17698750
Demirtaş AA, Karahan M, Erdem S et al (2021) Long-term effects of trabeculectomy in primary open-angle glaucoma on segmented macular ganglion cell complex alterations. Int Ophthalmol 41:2249–2263
doi: 10.1007/s10792-021-01840-y
pubmed: 33880684
Bormann C, Busch C, Rehak M et al (2022) Two year functional and structural changes-a comparison between trabeculectomy and XEN microstent implantation using spectral domain optical coherence tomography. J Clin Med 11:5840
doi: 10.3390/jcm11195840
pubmed: 36233707
pmcid: 9572517
Chua J, Kadziauskienė A, Wong D et al (2020) One year structural and functional glaucoma progression after trabeculectomy. Sci Rep 10:2808
doi: 10.1038/s41598-020-59792-9
pubmed: 32071369
pmcid: 7029027
Anon (2000) The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 130:429–440
doi: 10.1016/S0002-9394(00)00538-9